Accelerating research

and development of

new antibiotics and

alternatives

The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties.

Stay informed on NADP and subscribe to our Update.

NADP Vouchers

An important objective of NADP is to increase R&D productivity related to new antibiotics and alternatives. To promote the accelerated development of promising 'leads', NADP has developed a financing instrument specifically for this purpose: the NADP Vouchers.

These vouchers can be used in various phases of drug development to gain advice and intensive supervision of research projects from independent consultants or CROs that have specific knowledge and expertise pertinent to the pharmaceutical development process and clinical applications.

Latest News

New report calls for urgent action to avert antimicrobial resistance crisis

International organizations unite on critical recommendations to combat drug-resistant infections and prevent staggering number of deaths each year.

Read More...

NADP Annual Meeting, 22 May 2019, Paushuize, Utrecht ‘Accelerating antibiotic development in Europe’

NADP logo

The Netherlands Antibiotic Development Platform (NADP) is organizing its second annual meeting, titled ‘Accelerating antibiotic development in Europe’.

Read More...

Micreos Raises €30 Million for Endolysin Technology Set to Replace Antibiotics

Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema.

Read More...

NADP Partners

Supported by

NADP Partners

Supported by